Clinical Trials
2
Active:0
Completed:2
Trial Phases
1 Phases
Phase 4:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 4
1 (100.0%)Effective Analgesia During Routine Immunizations
Completed
- Conditions
- Pain
- First Posted Date
- 2011-06-08
- Last Posted Date
- 2015-07-29
- Lead Sponsor
- Children's Hospital of The King's Daughters
- Target Recruit Count
- 230
- Registration Number
- NCT01368861
- Locations
- 🇺🇸
Children's Hospital of The King's Daughters, Norfolk, Virginia, United States
A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy
Phase 4
Completed
- Conditions
- ALLERGIC ASTHMA
- Interventions
- Drug: ANTI-IGE THERAPY (XOLAIR)
- First Posted Date
- 2006-01-30
- Last Posted Date
- 2018-02-19
- Lead Sponsor
- Children's Hospital of The King's Daughters
- Target Recruit Count
- 13
- Registration Number
- NCT00283504
News
Novartis' OAV101 IT Gene Therapy Shows Motor Function Improvement in Older SMA Patients
Novartis' gene therapy, OAV101 IT (onasemnogene abeparvovec), has demonstrated improved motor function in older children (2-18 years) with spinal muscular atrophy (SMA) in a late-stage trial.
Novartis' Intrathecal Zolgensma Shows Positive Phase III Results for SMA Type 2
Novartis' intrathecal onasemnogene abeparvovec (OAV101 IT) met its primary endpoint in the Phase III STEER study for SMA Type 2.